COMPASS Pathways plc (NASDAQ:CMPS) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of COMPASS Pathways plc (NASDAQ:CMPS) by 4.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 110,939 shares of the company’s stock after purchasing an additional 4,981 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in COMPASS Pathways were worth $971,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of CMPS. ARK Investment Management LLC grew its stake in COMPASS Pathways by 7.6% during the fourth quarter. ARK Investment Management LLC now owns 2,618,871 shares of the company’s stock worth $22,915,000 after buying an additional 186,040 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of COMPASS Pathways in the 3rd quarter valued at $597,000. Armistice Capital LLC acquired a new position in shares of COMPASS Pathways during the 3rd quarter valued at $2,960,000. Vivo Capital LLC purchased a new stake in COMPASS Pathways during the 3rd quarter worth $11,899,000. Finally, AE Wealth Management LLC acquired a new stake in COMPASS Pathways in the 3rd quarter valued at $106,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $8.25 on Wednesday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.33 and a current ratio of 13.33. COMPASS Pathways plc has a 1 year low of $5.01 and a 1 year high of $12.75. The firm has a fifty day moving average of $9.84 and a 200-day moving average of $8.40. The company has a market cap of $511.01 million, a price-to-earnings ratio of -3.45 and a beta of 2.48.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, February 29th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.16). As a group, equities analysts anticipate that COMPASS Pathways plc will post -2.4 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CMPS. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research note on Thursday, April 18th. Morgan Stanley started coverage on COMPASS Pathways in a report on Monday, April 1st. They set an “overweight” rating and a $30.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a report on Friday, March 1st. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, COMPASS Pathways has an average rating of “Buy” and a consensus target price of $47.40.

Insiders Place Their Bets

In other COMPASS Pathways news, major shareholder Ekaterina Malievskaia sold 25,750 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $8.65, for a total transaction of $222,737.50. Following the sale, the insider now directly owns 4,036,154 shares of the company’s stock, valued at approximately $34,912,732.10. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director George Jay Goldsmith sold 15,740 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $10.58, for a total value of $166,529.20. Following the completion of the sale, the director now owns 4,079,107 shares of the company’s stock, valued at approximately $43,156,952.06. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Ekaterina Malievskaia sold 25,750 shares of the stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $8.65, for a total value of $222,737.50. Following the completion of the transaction, the insider now owns 4,036,154 shares in the company, valued at approximately $34,912,732.10. The disclosure for this sale can be found here. In the last quarter, insiders have sold 140,601 shares of company stock worth $1,338,911. Company insiders own 4.25% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.